Chemotherapy
induced nausea and vomiting (CINV) refers to the nausea and vomiting
associated with cancer chemotherapy. Various sources indicate that
approximately 70% to 80% cancer patients undergoing chemotherapy
exhibit nausea and vomiting as major symptoms. Chemotherapy induced
nausea and vomiting is an extremely debilitating condition. Although
there are currently a number of drugs available to manage CINV, they
do not effectively address the symptoms of this condition.
Browse
CINV Existing and Pipeline Drugs Market Report with Full TOC at
http://www.transparencymarketresearch.com/cinv-market.html
The
report on CINV existing and pipeline drugs market offers an
insightful and in-depth assessment of the current as well as future
market potential of CINV drugs. Aloxi (palonosetron), Zofran generic
(ondansetron), Kytril generic (granisetron), Emend (aprepitant) and
Akynzeo (netupitant-palonosetron FDC) are the major currently
available drugs extensively studied in the report. The historical
market size and forecast for each of these drugs (except for Akynzeo,
as the U.S. Food and Drug Administration (FDA) approved it only in
October 2014) in terms of revenue (USD Million) has been provided in
the report for the period from 2012 to 2020. In addition, the
compounded annual growth rate (CAGR) for each of these drugs has been
provided in the report for the forecast period from 2014 to 2020,
considering 2012 and 2013 as base years. The report also studies the
CINV patient pool for each of these drugs. The market size and CAGR
for Akynzeo have been determined for the years from 2015 to 2020.
The
report also provides extensive analysis of the pipeline drugs SUSTOL
(extended release granisetron injection) and rolapitant, including
the status of current clinical trials and future sales projection in
terms of USD million. The future sales projection of both these
pipeline drugs has also been provided for the North American and
European regions. The study also provides estimated patient pool for
both these pipeline drugs, broken down by North America and Europe.
In
this research study, the global market for CINV drugs has been
geographically segmented into four regions: North America, Europe,
Asia-Pacific and Rest of the World (RoW). The CINV drugs market size
and forecast in terms of revenue for each region has been provided
for the period from 2012 to 2020 along with the CAGR for the forecast
period from 2014 to 2020. The study also includes qualitative
analysis of the competitive scenario in these regions. The market
overview section of the report comprises qualitative analysis of the
overall market considering the factors determining the market
dynamics such as drivers, restraints and opportunities. The market
overview chapter provides information such as major subtypes of CINV,
the etiology of CINV, the pathogenesis of CINV, major emetogenic
chemotherapeutic agents, treatment recommendations for CINV and unmet
needs in the CINV market. A section on event impact analysis has also
been provided in the market overview chapter of the report on CINV
existing and pipeline drugs market.
For
further inquiries, click here :
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=776
The
report on chemotherapy induced nausea and vomiting drugs market also
includes a section on the competitive landscape of the market,
wherein the qualitative analysis of leading players in the global
CINV drugs market is presented. The report concludes with the
profiles of major players in the chemotherapy induced nausea and
vomiting drugs market such as GlaxoSmithKline plc, Helsinn Holding
S.A., Heron Therapeutics, Inc., Merck & Co., Inc. and Tesaro,
Inc. Each company profile comprises information such as company
overview, financial overview (selling, general and administrative
expenses, research and development expenses and annual revenue for
consecutive three years 2011, 2012 and 2013), current and pipeline
product portfolio, business strategies and recent developments.
The
global CINV existing and pipeline drugs market is segmented as
follows:
CINV
Existing and Pipeline Drugs Market Revenue (USD Million), by Major
Drugs
- Aloxi (palonosetron)
- Zofran Generic (ondansetron)
- Kytril Generic (granisetron)
- Emend (aprepitant)
- Akynzeo (netupitant-palonosetron)
- SUSTOL (extended release granisetron injection)
- Rolapitant
CINV
Existing and Pipeline Drugs Market Revenue (USD Million), by
Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Browse
all Pharmaceutical Market Research Reports @
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Sheela
AK
90
State Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-618-1030
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment